Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the second quarter ending June 30, 2025. The company disclosed a net loss attributable to common stockholders of $2.5 million, or $0.97 per share, compared to a net loss of $1.9 million, or $3.72 per share, for the same period in 2024. The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. As of June 30, 2025, Enveric held cash and cash equivalents totaling $2.8 million and raised net proceeds of $4.9 million for the first half of the year. CEO Joseph Tucker highlighted significant progress in the development of EB-003, the company's lead drug candidate, noting the confirmation of its dual mechanism of action involving the 5-HT₂A and 5-HT₁B receptors. This advancement positions EB-003 as a potential first-in-class therapeutic candidate. Enveric also expanded its intellectual property portfolio, securing a new patent grant and patent allowances in its EVM-301 and EVM-401 portfolios, enhancing its competitive position in neuroplastogen discovery.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814125233) on August 14, 2025, and is solely responsible for the information contained therein.
Comments